جست‌وجوی استاد و پژوهشگر

Robyn Honeaمشاهده پروفایل

پژوهشگر

• Neuroimaging
• Alzheimer's Disease
• Mitochondrial Genetics
• +۳ مورد دیگر

Robyn Honea, PhD, is a Research Associate Professor in the Department of Neurology at University of Kansas Medical Center. She directs the Neuroimaging Core of the University of Kansas Alzheimer’s Disease Research Center and the Brain Imaging and Neurogenetics Lab. Doctoral degree from Oxford University via NIMH Graduate Partnerships Award Postdoctoral training in Neurology at KU School of Medicine Member of Society for Neuroscience, Human Brain Mapping, KU Women and Medicine, and IStaart Her research focuses on Alzheimer's disease using multidisciplinary approaches combining brain imaging and genetic analysis . Key areas include: Mitochondrial genomics (TOMM40, APOE) Neuroimaging biomarkers (FDG-PET, fMRI, VBM) Lifestyle interventions (exercise, diet studies) Neurodegenerative pathways (tau phosphorylation, amyloid accumulation) From her 15 most recent publications (2025-2023), Dr. Honea's work demonstrates consistent focus on: Mitochondrial DNA effects on Alzheimer's pathology Genotype-imaging marker associations BDNF and GFAP protein interactions Exercise and dietary intervention impacts Neurofilament light chain analysis Multi-omics neurodegeneration research Dr. Honea mentors across academic levels, including junior faculty, postdoctoral fellows, graduate students, medical trainees, and undergraduate interns. She secures major funding from: National Institutes of Aging (K01 award) National Institutes of Health (R01 co-I) Alzheimer’s Association Dana Foundation Kansas City Area Life Sciences Initiative Frontiers Clinical and Translational Science Institute Her laboratory integrates neurogenetics with brain imaging to explore: Mitochondrial gene interactions Neurovascular coupling Metabolic-neurodegenerative links Structural-functional connectivity Polygenic risk assessment Imaging-genomic data fusion

• Cancer Epidemiology
• Genetic Epidemiology
• Cancer Genetics
• +۵ مورد دیگر

Timothy Rebbeck is Professor of Epidemiology in the Department of Biostatistics, Epidemiology, and Informatics at the Perelman School of Medicine, University of Pennsylvania. His research integrates cancer genetics with population health, focusing on genetic susceptibility and disparities in cancer outcomes across diverse populations, particularly African ancestry groups. His work centers on identifying cancer genes and characterizing their relationship with cancer occurrence and outcomes within demographic, biochemical, environmental, and physiological contexts. Key research areas include prostate, breast, and endometrial cancers, with emphasis on genetic epidemiology, tumor biomarkers, and the impact of structural determinants of health. Recent studies investigate neighborhood effects on telomere length, genetic risk prediction in prostate cancer, and community engagement in genomic research. Analysis of his 2022-2025 publications reveals leadership in large-scale genomic studies addressing racial disparities in prostate cancer diagnostics and treatment. His work spans Veterans Health Administration cohorts, international collaborations in Sub-Saharan Africa, and methodological advances in genetic risk modeling. A consistent theme is optimizing cancer screening protocols for high-risk populations while addressing barriers to care in underserved communities.

• Inborn errors of metabolism
• Newborn screening
• Clinical genetics
• +۳ مورد دیگر

Carol L. Greene, MD is a Professor of Pediatrics and Obstetrics & Gynecology & Reproductive Science at the University of Maryland School of Medicine. She serves as Director of the Pediatric Genetics Clinic, Co-Director of the Adult Genetics Clinic, and Medical Director of the Master’s in Genetic Counseling Program. She is a board-certified Clinical Geneticist with deep expertise in inborn errors of metabolism, newborn screening, and genetic testing policy. Education & Training: 1971–1974: B.S. in Biology, Stanford University 1974–1977: M.D., Albert Einstein College of Medicine 1977–1980: Pediatric Internship & Residency, Children’s Hospital of Los Angeles 1980–1983: Fellowship in Genetics, Stanford University School of Medicine Research Focus: Dr. Greene’s research spans biochemical genetics, newborn screening quality improvement, and public policy in genetic services. She has led initiatives with the CDC to improve genetic testing standards and serves as an advisor to Baby’s First Test, a national newborn screening education program. Clinical Interests: Her clinical work emphasizes inborn errors of metabolism, cardio-genetics, heme/onc-genetics, and cleft palate genetics. She provides comprehensive care across all age groups, integrating cutting-edge diagnostics with long-term management strategies. Scientific Contributions: With over 45 peer-reviewed publications and multiple book chapters, Dr. Greene has shaped the fields of metabolic genetics and newborn screening. Her work includes seminal studies on phenylalanine hydroxylase deficiency, glutaric aciduria, and mitochondrial disorders. Awards & Honors: Best Doctors in America (1994–Present) Baltimore Magazine “Top Docs” (2007, 2010–2014, 2016) Alexander J. Shaffer Teaching Award (2010) Founding Fellow, American College of Medical Genetics and Genomics Fellow, American Academy of Pediatrics Leadership Roles: Dr. Greene has served as President of the Society for Inherited Metabolic Disorders and is actively involved in national policy committees, including the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children. She also maintains a 20% Intergovernmental Personnel Agreement with the CDC to advance public health genetics initiatives. Laboratory & Clinical Teams: She directs multidisciplinary teams in pediatric and adult genetics clinics, oversees genetic counseling training, and collaborates with national laboratories to standardize genetic testing practices. Her clinical service includes participation in specialized clinics for mitochondrial disorders, metabolic diseases, and craniofacial anomalies.

• Medicinal Chemistry
• Oncopharmacology
• Anti-Cancer Drug Discovery
• +۸ مورد دیگر

Dr. Vincent C.O. Njar is a Professor in the Department of Pharmacology & Physiology at the University of Maryland School of Medicine, with concurrent roles as Medicinal Chemistry Group Leader at the Center for Biomolecular Therapeutics (CBT) and Full Member at the Marlene and Stewart Greenebaum Cancer Center. He is a distinguished medicinal chemist and oncopharmacologist known for developing small-molecule anti-cancer agents, particularly galeterone and its analogs. His academic journey includes B.Sc. (1976) and Ph.D. (1980) from the University of Ibadan and University College London, followed by postdoctoral training at the Worcester Foundation. Education: University of Ibadan - B.Sc. Chemistry (1976) University College London - Ph.D. Organic Chemistry (1980) Dr. Njar’s research spans Mechanistic Oncopharmacology and Molecular Targeting , focusing on: Design of retinoidal/steroidal compounds targeting CYP enzymes and androgen receptors Development of MNK1/2 degraders (e.g., VNLG-152R) for translational oncology Mechanistic studies on apoptosis induction and metastasis inhibition Translational research bridging preclinical models to clinical trials His recent publications emphasize: Novel deuterated compounds for enhanced stability Mechanistic insights into kinase degradation Drug repurposing for dermatological and neurological cancers Therapeutic strategies for racial disparities in prostate cancer Pharmacokinetic optimization for clinical translation Combination therapies synergizing with gemcitabine Dr. Njar founded Terpene Pharmaceuticals LLC in 2014 and led galeterone through Phase III trials (ARMOR3-SV) for castration-resistant prostate cancer. His work spans epigenetic regulation via HDAC inhibitors, autophagy modulation , and computational drug design for multi-target agents. Current research explores cholesterol biosynthesis and Stat5 inhibition in cancer progression. Key Collaborations: Angela Brodie (University of Maryland School of Medicine) Kimmel Cancer Center Terpene Pharmaceuticals

• Virology
• Immunology
• Neuroscience
• +۶ مورد دیگر

Professor Astrid Iversen is a virologist and immunologist at the Nuffield Department of Clinical Neurosciences within the University of Oxford . She is affiliated with the Weatherall Institute of Molecular Medicine , Kellogg College , and the MRC Doctoral Training Partnership . Her research focuses on the co-evolution of pathogens and human immune responses , particularly in neurological contexts. MD, PhD Member, UK Parliament's & Government's COVID-19 Outbreak Expert Database Research interests span multiple interrelated fields: Virology: HIV-1, SARS-CoV-2, and JC virus (PML) Immunology: T-cell responses, HLA adaptation, immune evasion Neuroscience: Neurological complications in HIV, CNS inflammatory diseases post-vaccination Evolutionary Genomics: Ancient DNA studies tracing pathogen-immune co-evolution over 12,500 years Recent publications demonstrate expertise in: Tracking pathogen distribution in ancient Eurasia Genetic risk factors for autoimmune diseases Immune response dynamics in viral infections

Rodolphe Barrangouمشاهده پروفایل

استاد

• CRISPR
• Genome Editing
• Food Microbiology
• +۴ مورد دیگر

Rodolphe Barrangou is the Todd R. Klaenhammer Distinguished Professor in the Department of Food, Bioprocessing and Nutrition Sciences at North Carolina State University's College of Agriculture and Life Sciences. A molecular biologist of international renown, he co-discovered the bacterial immune function of CRISPR-Cas systems while at Danisco/DuPont, revolutionizing genome editing and food production. His career spans 9 years in industrial R&D followed by academic leadership since 2013. His educational background includes: BS in Biological Sciences, René Descartes University (1996) MS in Biological Engineering, Université de Technologie de Compiègne (2000) MS in Food Science, North Carolina State University (2004) PhD in Functional Genomics, North Carolina State University (2004) MBA, University of Wisconsin-Madison (2011) Barrangou's research focuses on CRISPR-Cas systems as bacterial adaptive immunity, with applications spanning food microbiology, microbiome engineering, and sustainable agriculture. His lab pioneers CRISPR-based solutions for phage resistance in dairy cultures, microbiome modulation, and forest tree improvement for carbon sequestration. He has established CRISPR as foundational technology in industrial fermentation, where CRISPR-enhanced cultures now produce billions of servings of yogurt and cheese globally. His recent publications reveal accelerating applications in plant biotechnology, antimicrobial development, and microbiome therapeutics. Key trends include multiplex genome editing in crops, phage-delivered CRISPR systems, and climate-resilient forestry applications – demonstrating CRISPR's evolution from basic discovery to multi-sector impact. Major recognitions include: Canada Gairdner International Award (2016) Warren Alpert Prize from Harvard Medical School (2016) Triple academy membership (National Academies of Sciences, Engineering, and Inventors) National Inventors Hall of Fame induction (2023) 26 issued U.S. patents including foundational CRISPR food applications As an entrepreneur, Barrangou co-founded Intellia Therapeutics, Locus Biosciences, TreeCo, Ancilia Biosciences, and CRISPR Biotechnologies. He serves as Editor-in-Chief of The CRISPR Journal and has built the global CRISPR community through organizing the first five international conferences. His current work applies CRISPR to sustainable forestry and next-generation food systems, aiming to impact both current and future global populations through carbon-capturing trees and climate-resilient crops. His laboratory maintains active collaborations across academia and industry, with particular emphasis on translating CRISPR discoveries into real-world applications for food security and environmental sustainability.

Malte Spielmannمشاهده پروفایل

پژوهشگر

• Structural Genomics
• Developmental Disorders
• 3D Genome Organization
• +۳ مورد دیگر

Malte Spielmann is a Researcher at the Max Planck Institute for Molecular Genetics in the Human Molecular Genomics department. His work focuses on structural variants, 3D genome organization, and their role in developmental disorders and rare diseases. Key contributions in Nature , Nature Communications , and Genes & Chromosomes journals Developed frameworks for integrating Hi-C with genome sequencing to resolve complex rearrangements Research Themes : Decoding how structural variants alter gene regulation via chromatin architecture Elucidating phase separation and nucleolar dysfunction in genetic syndromes Pioneering single-cell phenotyping for developmental disease mechanisms Article Trends (2021-2025) highlight interdisciplinary approaches combining: Hi-C and long-read sequencing for TAD analysis Single-cell RNA-seq in limb malformations and neurodegeneration Epigenetic repression and enhancer hijacking in congenital defects

Herbert Kim Lyerlyمشاهده پروفایل

استاد

• Cancer Immunology
• Tumor Immunology
• Immunotherapy
• +۳ مورد دیگر

Herbert Kim Lyerly serves as the George Barth Geller Distinguished Professor of Immunology and holds joint appointments as Professor of Surgery and Professor of Pathology at Duke University School of Medicine. He maintains critical affiliations with the Duke Cancer Institute, Duke-Margolis Center for Health Policy (as Core Faculty), Duke Regeneration Center, and Duke Global Health Institute, directing translational initiatives through the Surgical Sciences Center for Applied Therapeutics and Environmental Health Scholars Program. His educational foundation includes an M.D. from UCLA (1983) and distinguished scholarly recognition as a Life Member of Clare Hall, University of Cambridge (2022-2030), with prior Visiting Fellowships at Cambridge in 2019 and 2022. This international engagement complements his deep institutional roots at Duke. Dr. Lyerly's research program centers on overcoming immunotherapy resistance in breast and prostate cancers through innovative vaccine platforms targeting oncogenic drivers like ESR1 mutations and androgen receptor variants. His lab pioneers spatial analysis of tumor heterogeneity using mouse models and develops ultrasound-enhanced delivery systems (e.g., PULSE technology) to improve intratumoral immunotherapy penetration. Concurrently, he investigates environmental health disparities, particularly air pollution's impact on cancer outcomes and multimorbidity. Analysis of his 15 most recent publications reveals accelerating innovation in three domains: (1) Mechanistic studies of antibody-drug conjugates like trastuzumab deruxtecan, focusing on payload release and immunomodulation; (2) Next-generation vaccine strategies using mRNA-LNP platforms to target treatment-resistant mutations; and (3) Advanced imaging techniques (hyperspectral, spatial) for mapping tumor-immune interactions. These efforts consistently bridge basic discovery and clinical application. His leadership in sponsored research is evidenced by 10 major concurrent grants totaling over $50 million, including a 10-year NIEHS Environmental Health Program (2019-2029), DoD-funded breast cancer initiatives through 2028, and Susan G. Komen-supported work on obesity-tumor interactions in TNBC. These projects integrate basic science, clinical trials, and population health approaches. Dr. Lyerly directs the Surgical Sciences Center for Applied Therapeutics, which develops novel drug delivery platforms, and co-leads the Environmental Health Scholars Program training next-generation researchers in pollution-cancer linkages. His work with the Duke-Margolis Center actively shapes health policy frameworks for cancer care delivery and clinical trial diversity.

Jason Mezeyمشاهده پروفایل

استاد

• Computational Biology
• Genetic Research
• Biomedicine
• +۵ مورد دیگر

Dr. Jason Mezey is a Professor of Genetic Medicine and Systems and Computational Biomedicine at Weill Cornell Medical College. His research focuses on the intersection of computational biology, genetics, and pulmonary medicine, particularly examining how environmental factors like smoking affect airway epithelial biology. B.A., University of Pennsylvania (1994) Ph.D., Yale University (2000) Key research areas include genetic regulation of airway stem cells , epigenetic responses to environmental toxins , and computational methods for gene network reconstruction . Notable work involves characterizing the small airway epithelium's response to cigarette smoke and developing synthetic clinical trial data frameworks. Current NIH-funded projects include leading a Phase IA/IB Study of AAVrh.10hFXN Therapy for Friedreich's Ataxia cardiomyopathy and investigating basal cell biology in early COPD . He utilizes adeno-associated virus vectors and computational models to address gene therapy and disease mechanisms. External relationships include consulting roles with H2 Analytics, LLC and Medidata Solutions , alongside equity ownership in H2 Analytics. His work bridges academic research with biotechnology innovation.

Esther van der Knaapمشاهده پروفایل

استاد

• Plant Genetics
• Molecular Biology
• Tomato Domestication
• +۴ مورد دیگر

Esther van der Knaap is a Professor at the University of Georgia within the College of Agricultural & Environmental Sciences. She is affiliated with the Horticulture department and the Institute of Plant Breeding, Genetics and Genomics (IPBGG) . Her research focuses on molecular mechanisms regulating tomato fruit shape and size, with applications in crop improvement and climate resilience. Education: Ph.D. in Genetics, Michigan State University (1998) B.S./M.S. in Plant Pathology, Wageningen University (1990) Dr. van der Knaap’s work explores fruit development genetics in Solanaceous crops. She investigates structural genomic variants , gene regulatory networks , and metabolic pathways to enhance agricultural productivity. Her studies span tomato domestication , stress adaptation , and flavor preservation . Recent publications highlight advances in CRISPR-based gene editing , cell segmentation technology , and methyl salicylate metabolism . Her team’s tomato genome analyses reveal insights into domestication history and yield optimization , funded by NSF and USDA grants. She leads the Esther van der Knaap Lab at UGA’s Center of Applied Genetic Technologies (CAGT). Collaborative efforts include the CAES Vegetables Team and The Plant Center .

Jean Morrisonمشاهده پروفایل

استادیار

• Statistical Genetics
• Genomics
• Causal Inference
• +۴ مورد دیگر

Jean Morrison serves as the John G Searle Assistant Professor in the Department of Biostatistics at the University of Michigan School of Public Health, a position she assumed in 2020 following postdoctoral work at the University of Chicago and doctoral studies at the University of Washington. Her academic trajectory reflects deep specialization in statistical methodologies for complex biological systems. Her educational foundation includes: PhD in Biostatistics, University of Washington (2016) BA in Mathematics, University of Chicago (2009) Dr. Morrison's research centers on statistical genetics and genomics , with pioneering work in high-dimensional phenotype analysis (e.g., brain imaging, proteomics, and clinical trait clusters). She develops advanced causal inference frameworks, notably for Mendelian randomization with robust pleiotropy handling, and integrates empirical Bayes methodologies with deep learning for genomic applications. Her approach emphasizes biologically interpretable low-rank representations of genetic associations. Recent publications (2022-2025) reveal escalating focus on multi-omics integration (genome, transcriptome, proteome), probabilistic fine-mapping of causal variants, and methodological refinements for Mendelian randomization. Her work increasingly addresses genetic pleiotropy complexity through factor analysis and develops computational tools like GWASBrewer for realistic simulation of genetic data. No scientific awards are documented in available sources. Similarly, public records contain no details regarding student advising, research grants, or laboratory leadership.

Goncalo Abecasisمشاهده پروفایل

استاد

• Statistical Genetics
• Human Genetics
• Biostatistics
• +۵ مورد دیگر

Goncalo Abecasis is the Felix E. Moore Collegiate Professor of Biostatistics at the University of Michigan School of Public Health, where he leads the Center for Statistical Genetics. He received his DPhil in Human Genetics from the University of Oxford in 2001 and joined the University of Michigan faculty that same year. His research focuses on developing statistical and computational tools for identifying genetic variants associated with human disease and variation. His research interests include the development of analytical methods for mapping complex traits, utilization of linkage disequilibrium in gene mapping, quantitative trait analysis, and characterization of human genetic variation. He has pioneered computational approaches that enable the analysis of large genomic datasets generated by high-throughput technologies. His work addresses practical challenges in handling real-world genetic data, including genotype error detection and relationship verification. Abecasis has developed numerous widely-used software tools including Merlin (for pedigree analysis), MACH (for haplotype estimation), LAMP (for association testing), QTDT (for quantitative trait analysis), GOLD (for linkage disequilibrium visualization), and GRR (for relationship error detection). His publications span statistical genetics methodology, software development, and applications to diseases including diabetes, glaucoma, age-related macular degeneration, schizophrenia, and aging-related traits. His recent work involves large-scale genome-wide association studies with hundreds of thousands of participants, focusing on complex traits related to substance use, cardiovascular health, metabolic disorders, and eye diseases. The computational tools he develops are used in hundreds of gene-mapping projects worldwide. Abecasis collaborates extensively with researchers studying diabetes (Dr. Michael Boehnke), eye diseases (Drs. Julia Richard and Anand Swaroop), schizophrenia (Dr. Maria Karayiorgou), and aging-related traits (Dr. David Schlessinger).

Ryan Hernandezمشاهده پروفایل

استاد

• Population Genetics
• Computational Biology
• Pharmacogenomics
• +۶ مورد دیگر

Dr. Ryan Hernandez is a Professor at the University of California San Francisco (UCSF) , affiliated with the Department of Bioengineering and Therapeutic Sciences . He co-leads the Torgerson-Hernandez Lab (THeLab) and serves as Co-Director of multiple training programs including the Biological and Medical Informatics Graduate Program (BMI) , Genentech-UCSF School of Pharmacy Fellowship Program , and UCSF PREP . PhD in Biometry, Cornell University (2007) MS in Biometry, Cornell University (2003) BA in Mathematics, Pitzer College (2003) His research focuses on human genetic variation using whole-genome sequencing to study disease susceptibility and drug response . Key areas include computational biology , population genetics , and systems pharmacology . Recent publications emphasize admixed populations , metabolomic biomarkers , and genetic simulation tools . Scientific awards include the Sloan Research Fellowship (2013-2016) and Basic Science Award in HIV/AIDS (2014-2015). He also received Outstanding Teaching Assistant recognition from Cornell in 2007.

Carl Andersonمشاهده پروفایل

استاد

• Statistical Genetics
• Genomics of Inflammation and Immunity
• Genetic Epidemiology
• +۷ مورد دیگر

Carl Anderson serves as Head of the Human Genetics Programme and Senior Group Leader at the Wellcome Sanger Institute, where he leads the Genomics of Inflammation and Immunity research group. His work focuses on leveraging human genetic variation to gain causal insights into disease biology, with particular emphasis on inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC). Dr. Anderson completed his academic training with a BSc and MSc in Biomedical Science and Genetic Epidemiology at the University of Sheffield, followed by a PhD in Quantitative Genetics at the University of Edinburgh under Peter Visscher, with the final two years conducted at the University of Brisbane. In 2007, he joined the Wellcome Trust Case Control Consortium at Oxford to work on IBD genetics before moving to the Sanger Institute where he established his independent research program. His research integrates cutting-edge genomic technologies including genome-wide association studies (GWAS), whole-exome and whole-genome sequencing, single-cell RNA sequencing, and CRISPR-based functional screens. His group has identified more than 280 genetic loci associated with IBD, uncovering novel disease mechanisms such as the role of autophagy in IBD pathogenesis. Several genes identified through his research are now targets of drugs undergoing clinical trials for immune-mediated disorders. In 2016, he strategically expanded his group to include wet lab capabilities, enabling high-throughput cellular screening approaches that bridge genetic associations with biological mechanisms. Analysis of his recent publications reveals increasing integration of multi-omics approaches and computational methods to translate genetic associations into biological understanding. His work shows growing emphasis on translational applications including polygenic risk scoring, treatment response prediction, and fine-mapping of causal variants across immune-mediated diseases. Dr. Anderson is deeply committed to collaborative science as demonstrated by his longstanding membership in the UK IBD Genetics Consortium, co-PI role on the IBD Bioresource (over 30,000 patients), and participation in the International IBD Genetics Consortium management committee. His open and collaborative approach has established him as a central figure in the IBD research community. As Director of Graduate Studies at the Sanger Institute, he mentors the next generation of genomic scientists. His group website (www.andersonlab.info) highlights ongoing projects in genetic architecture of immune diseases, functional validation of disease-associated variants, and development of precision medicine approaches for IBD patients.

Emma Davenportمشاهده پروفایل

استاد

• Functional Genomics
• Clinical Data Integration
• Genetic Variation in Disease Response
• +۷ مورد دیگر

Dr. Emma Davenport is a Group Leader at the Wellcome Sanger Institute within the Human Genetics Programme, where she leads the Davenport Group focused on Functional Genomics of Variation in Disease Response. She joined the Sanger Institute in October 2018 after completing postdoctoral research at Harvard Medical School in Professor Soumya Raychaudhuri's lab at Brigham and Women's Hospital and the Broad Institute. Her research integrates functional genomics and clinical data to understand how genetics contributes to patient-to-patient heterogeneity in disease severity and treatment response. Dr. Davenport's primary research interests focus on diseases involving systemic inflammation such as sepsis and systemic lupus erythematosus (SLE). Her work employs sophisticated analytical methods to analyze functional genomics data from hundreds of patient cohorts, integrating this with clinical information. She specializes in transcriptomic profiling to stratify patients and understand individual responses to infections and autoimmune conditions. Her group investigates expression quantitative trait locus (eQTL) interactions to uncover how environmental factors modulate genetic regulatory effects on gene expression. Analysis of Dr. Davenport's publication record reveals a strong focus on patient stratification through transcriptomic signatures, particularly in sepsis where her group identified the Sepsis Response Signature (SRS) endotypes. Her research spans multiple areas including host-pathogen interactions, drug response variability, and single-cell eQTL mapping in autoimmune diseases. Recent work has expanded into multi-omics approaches, integrating genomic, transcriptomic, and proteomic data to understand the molecular basis of disease heterogeneity. Dr. Davenport has successfully mentored numerous PhD students and postdoctoral fellows who have contributed significantly to her research program. Her group collaborates extensively with clinical partners through initiatives like the Genomics Advances in Sepsis (GAinS) study and the Bioresource for Adult Infectious Diseases (BioAID), applying genomic approaches to improve diagnosis and treatment of infectious diseases.